InflaRx N.V., a biopharmaceutical company focused on anti-inflammatory therapies, announced it will publish its financial and operating results for the first quarter of 2026 on May 7, before the market opens. The company will not hold a conference call to discuss the results. InflaRx is known for its lead drug candidates izicopan and vilobelimab, targeting inflammatory diseases by inhibiting the complement system. Investors will be watching for updates on the progress of these therapies and any regulatory developments.
STMicroelectronics announced a $1.5 billion issuance of new convertible senior bonds in two tranches, with maturities of 5 and 7 years, alongside the early repayment of $750 million of zero-coupon convertible bonds due in 2027. The new bonds offer fi...
Regentis Biomaterials shares surged over 500% intraday before falling 9.15% in after-hours trading following the company's announcement that it withdrew its Registration Statement for a public offering. The regenerative medicine firm decided not to p...
Elon Musk's SpaceX recently went public, raising questions about a potential IPO for its Starlink subsidiary. Data from prediction market Kalshi shows only a 7-10% chance of a Starlink IPO announcement before mid-2027. Meanwhile, Musk predicts SpaceX...
Goodfirms has published its 2026 rankings of top technology service providers across six categories: mobile app, software, web development, digital marketing, SEO, and AI development. These rankings are based on over 1.2 million verified client revie...
Alvotech announced a $152 million public offering and concurrent private placement of ordinary shares priced at $3.75 each. The public offering includes 22.7 million shares, with an option for underwriters to buy an additional 3.4 million shares. The...
